Equities

Changmao Biochemical Engineering Co Ltd

Changmao Biochemical Engineering Co Ltd

Actions
  • Price (EUR)0.054
  • Today's Change0.00 / 0.00%
  • Shares traded--
  • 1 Year change-28.00%
  • Beta--
Data delayed at least 15 minutes, as of Nov 15 2024 07:08 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in CNYIncome statement in CNYView more

Year on year Changmao Biochemical Engineering Co Ltd's revenues fell -12.73% from 730.03m to 637.08m. This along with an increase in the cost of goods sold expense has contributed to a reduction in net income from a gain of 81.42m to a loss of 86.06m.
Gross margin0.05%
Net profit margin-16.66%
Operating margin-11.51%
Return on assets-8.56%
Return on equity-15.86%
Return on investment-12.16%
More ▼

Cash flow in CNYView more

In 2023, Changmao Biochemical Engineering Co Ltd increased its cash reserves by 49.27%, or 29.56m. Cash Flow from Financing totalled 153.84m or 24.15% of revenues. In addition the company used 2.35m for operations while cash used for investing totalled 122.11m.
Cash flow per share-0.1371
Price/Cash flow per share--
Book value per share1.29
Tangible book value per share1.29
More ▼

Balance sheet in CNYView more

Changmao Biochemical Engineering Co Ltd has a Debt to Total Capital ratio of 45.78%, a higher figure than the previous year's 18.27%.
Current ratio0.8662
Quick ratio0.4914
Total debt/total equity0.8446
Total debt/total capital0.4578
More ▼

Growth rates in CNY

SmartText is unavailable
Div yield(5 year avg)5.08%
Div growth rate (5 year)--
Payout ratio (TTM)--
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago
-343.84
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.